What Azenta, Inc. told the SEC could break it.

Azenta's GENEWIZ/Multiomics genomics business has a significant operation in China — a ~240,000 sq ft owned laboratory in Suzhou — and the company expects its proportion of sales to China customers to increase due to this hub. At the same time, amid U.S.–China geopolitical tensions and biotech-decoupling pressure, Azenta has started processes to move certain operations outside of China and began repatriating its China cash (≈$20M) to the U.S. in fiscal 2025. This concentrates a key revenue-generating operation in a single, geopolitically sensitive jurisdiction: export controls, sanctions/BIOSECURE-style restrictions, data-transfer rules, or U.S.–China trade actions could disrupt the China genomics operation or its cross-border customer base. A distinctive China-operations/geopolitical concentration.

“the proportion of our sales to customers in China will increase, due in large part to our significant genomic services operation in China. While we continue to have genomic services operations in China, we also started processes to move certain operations outside of China.”

Azenta obtains many key components on an as-needed, purchase-order basis from numerous suppliers, but in some cases has only a single source of supply for key components and materials used to manufacture its products (e.g., automated sample-storage and cryogenic systems). A portion of its supply comes from Asia, including China, sometimes from suppliers it has limited history with. A failure, quality issue, price spike, or interruption at a single-source or Asia-based supplier could delay product manufacturing and shipments. Suppliers unnamed, so a sole-source/supplier-concentration risk.

“In some cases, we have only a single source of supply for key components and materials used in the manufacturing of our products.”

Azenta flags that in April 2025 the U.S. imposed broad tariffs on imports from virtually all countries, with particularly high tariffs on China (most non-China tariffs were later suspended/reduced temporarily), prompting retaliatory tariffs from some countries. Given Azenta sources components from Asia/China and runs significant genomics operations in China, escalating China-focused tariffs and trade tensions could raise component/manufacturing costs, reduce trade volume, and add uncertainty to its cross-border operations. A cited trade-policy/tariff exposure layered on its China footprint.

“in April 2025, the United States imposed broad tariffs on imports from virtually all countries, with particularly high tariffs on imports from China.”